Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II

NCT01265225 is registered in ClinicalTrials.gov with The Baruch Padeh Medical Center, Poriya as lead sponsor.

NCT NCT01265225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01265225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II
Lead sponsor
The Baruch Padeh Medical Center, Poriya
Phase
Observational
Overall status
Withdrawn
Start date
February 28, 2011
Completion date
April 30, 2013
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer